Prism AI
Prism AI is a University of Utah spinoff applying a proprietary quantum mechanics-based AI technique to genomic and molecular data, enabling biotech and pharma customers to optimize clinical trial design, identify drug targets, and predict cancer outcomes from small patient cohorts.
- Company typePrivate
- Founded2024
- HeadquartersSalt Lake City, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Prism AI does
Prism AI is a University of Utah spinoff founded in 2024 and headquartered in Salt Lake City, building what it describes as an operating system for drug development and biomarker discovery. Its core technology is a quantum mechanics-based AI/ML approach using multitensor comparative spectral decompositions to analyze millions to billions of molecular features (tumor DNA, blood DNA, tumor RNA) from patient cohorts as small as 20-100 individuals, a regime where conventional AI is reported to underperform due to data scarcity. The company has validated the method against a neuroblastoma cohort of 101 patients across approximately 6 million features, discovering new predictors of patient life expectancy that it claims consistently outperform standard biomarkers and replicate across hospitals. Therapeutic targets identified by the AI are experimentally validated using CRISPR-Cas9 gene editing.
The portfolio also extends beyond therapeutics. Under the Prism AI Therapeutics sub-brand, the company addresses biotech and pharmaceutical customers seeking to optimize clinical trial design and drug target identification. Separately, a Singapore-incorporated entity (PRISM AI PTE. LTD.) launched PYRA, a multi-agent coordination system with a Credit System and reputation-based distribution model, in March 2026, and additional Developer Analytic Tools automate insight extraction from session replays. Leadership comprises CEO Asaf Zviran, Chief Science Officer Orly Alter, and CTO Daniel Shabtai. Business model mechanics are not publicly disclosed: pricing is not published, no revenue figure is available, no paying customers are named, and the only funding entry records $0 from Evolution VC Partners and Vela Partners in early 2025.
Prism AI firmographics
Firmographics- Name
- Prism AI
- Legal name
- PRISM AI PTE. LTD.
- Website
- https://prism-ai.com
- Company type
- Private
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Prism AI is a University of Utah spinoff applying a proprietary quantum mechanics-based AI technique to genomic and molecular data, enabling biotech and pharma customers to optimize clinical trial design, identify drug targets, and predict cancer outcomes from small patient cohorts.
- Ownership category
- akta.pro rank
Prism AI industry classification
Industry- Product category
- AI Drug Discovery
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), End-to-End Enterprise AI Platforms (MLOps & Model Lifecycle Management) (HDAEANAA), Industry/Domain Analytics Solutions & Accelerators (BPAEAHAK)
Keywords
Where Prism AI is headquartered
LocationHeadquarters
- HQ city
- Salt Lake City
- HQ country
- United States
- HQ region
- North America
Markets served
Prism AI business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel
Prism AI product offering
Product offeringCore offering
Prism AI develops quantum mechanics-based AI/ML algorithms that analyze millions to billions of molecular features from small patient cohorts (20-100 people) to predict cancer treatment outcomes and identify optimal drug targets. The company offers Prism AI Therapeutics for biotech and pharma clinical trial optimization, PYRA—a multi-agent system that coordinates AI agents through a unified execution network—and developer analytic tools that automate insight extraction from session replays.
Product overview
Prism AI operates as a multi-product technology company with distinct offerings across different domains. The portfolio includes Prism AI Therapeutics (a healthcare/biotech spinoff using quantum AI for cancer research), PYRA (a multi-agent coordination system for AI execution), and Developer Analytic Tools (session replay analytics for product teams). These products address different market segments including biotech/pharmaceutical research, AI agent orchestration, and developer productivity tools.
Differentiator
Problem solved
Functional benefit
Brands
- PYRA: A multi-agent system designed to coordinate AI agents through a unified execution network where users submit objectives and the platform routes tasks across multiple agents to produce combined outputs. Includes an economic layer featuring a Credit System and reputation-based distribution model.
Products and services
- Prism AI Therapeutics A University of Utah spinoff commercializing quantum AI algorithms for biotech and pharmaceutical companies to identify optimal patient subgroups and drug targets for clinical trials, validated through CRISPR-Cas9 gene editing.
- PYRA A multi-agent system designed to coordinate AI agents through a unified execution network where users submit objectives and the platform routes tasks across multiple agents to produce combined outputs, featuring an economic layer with a Credit System and reputation-based distribution model.
- Developer Analytic Tools
Quantifiable outcome
- Discovered two new predictors of neuroblastoma patient life expectancy that consistently outperform standard biomarkers
- +2 more outcomes
Companies that use Prism AI
Customer profileSegments1 record
Ideal customer profiles2 records
Prism AI technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature3 records
Prism AI partnerships and signals
Strategic signalRecent moves8 records
Expansion highlights4 records
Prism AI competitors and assessment
Company assessmentDirect peers
- Owkin: AI for clinical and translational research using patient-level data to discover biomarkers and predict treatment outcomes — the closest peer to Prism's biomarker and subgroup discovery from patient cohort data.
- Insitro: Machine-learning-enabled drug discovery company combining wet-lab biology with predictive models to identify targets and patient subgroups — closely aligned with Prism's small-cohort, biology-grounded AI approach.
- BenevolentAI: AI platform for drug discovery and biomarker identification using biomedical knowledge graphs and ML — comparable AI-for-discovery and target-identification value proposition.
- GNS Healthcare: Causal AI platform for patient-level outcome prediction and biomarker discovery from real-world and clinical data — closely aligned with Prism's predictive modeling from small patient cohorts.
- PathAI: AI platform for pathology-based biomarker discovery and diagnostic development — comparable on AI-driven biomarker identification supporting pharma clinical programs.
- Exscientia: AI-driven precision medicine and drug discovery company using machine learning to design therapeutics and stratify patients — comparable end-to-end platform positioning to Prism AI Therapeutics.
- Schrödinger: Physics-based and AI-driven molecular simulation platform for drug discovery and materials — comparable on computationally intensive molecular modeling feeding pharma R&D workflows.
- Recursion Pharmaceuticals: AI-driven drug discovery platform using high-throughput biology and machine learning to identify therapeutics — directly comparable to Prism AI Therapeutics on AI-for-drug-development positioning.
Broad incumbents
- ConcertAI: AI solutions for clinical and real-world evidence analytics serving pharma R&D and commercialization — overlapping incumbent serving the same biotech/pharma buyer with adjacent analytics offerings.
- Tempus Labs: Large AI-enabled precision medicine company aggregating clinical and molecular data for oncology — broader incumbent that overlaps with Prism's biomarker and patient-stratification use cases for pharma/biotech customers.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Prism AI social profiles
Digital presencePrism AI financial estimates
Financial estimateRevenue estimate
Valuation estimate
Prism AI leadership team
Management profileNumber of profiles
Profiles3 records
Prism AI funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Prism AI M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Prism AI
What does Prism AI do?
Prism AI develops quantum mechanics-based AI/ML algorithms that analyze millions to billions of molecular features from small patient cohorts (20-100 people) to predict cancer treatment outcomes and identify optimal drug targets. The company offers Prism AI Therapeutics for biotech and pharma clinical trial optimization, PYRA—a multi-agent system that coordinates AI agents through a unified execution network—and developer analytic tools that automate insight extraction from session replays.
Is Prism AI a public or private company?
Prism AI is a private company. It is classified as venture growth investor backed and is currently operating.
When was Prism AI founded?
Prism AI was founded in 2024. It employs 1 to 10 people.
Where is Prism AI based?
Prism AI is headquartered in Salt Lake City, United States, in the North America region.
Who are Prism AI's main competitors?
Direct peers on record are Owkin, Insitro, BenevolentAI, GNS Healthcare, PathAI, Exscientia, Schrödinger and Recursion Pharmaceuticals. Broad incumbents are ConcertAI and Tempus Labs.
Does Prism AI have an API?
No public API is recorded for Prism AI.
What industry is Prism AI in?
Prism AI's product category is AI Drug Discovery. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 8731.